A Phase I study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor xeruborbactam (XER) administered as the isobutyryloxymethyl oral prodrug to healthy adult subjects
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Xeruborbactam (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- 23 Jan 2025 New trial record